Detalhe da pesquisa
1.
Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
Lancet
; 403(10422): 171-182, 2024 Jan 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38104577
2.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37646671
3.
Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study.
Breast Cancer Res Treat
; 195(3): 341-351, 2022 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-35986801
4.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1144-1152, 2022 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34289656
5.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33794206
6.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
Inglês
| MEDLINE | ID: mdl-30770396
7.
Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer.
Breast Cancer Res Treat
; 181(2): 233-248, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32274666
8.
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Breast Cancer Res Treat
; 183(1): 227-237, 2020 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-32613539
9.
A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Blood
; 131(16): 1805-1808, 2018 04 19.
Artigo
Inglês
| MEDLINE | ID: mdl-29386196
10.
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.
Blood
; 128(11): 1458-64, 2016 09 15.
Artigo
Inglês
| MEDLINE | ID: mdl-27458003
11.
Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.
Br J Haematol
; 168(5): 663-70, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25316653
12.
Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma.
Leuk Lymphoma
; 65(2): 235-241, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38264906
13.
Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 131(1): 111-6, 2012 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-21898114
14.
Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: a phase II risk-adapted design.
Leuk Lymphoma
; 63(12): 2889-2896, 2022 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35972020
15.
Morphologic and Genomic Characteristics of Breast Cancers Occurring in Individuals with Lynch Syndrome.
Clin Cancer Res
; 28(2): 404-413, 2022 01 15.
Artigo
Inglês
| MEDLINE | ID: mdl-34667028
16.
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring.
Clin Cancer Res
; 28(1): 45-56, 2022 01 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34615723
17.
Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience.
Leuk Lymphoma
; 62(9): 2177-2183, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-33779474
18.
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma.
J Clin Oncol
; 39(20): 2257-2265, 2021 07 10.
Artigo
Inglês
| MEDLINE | ID: mdl-33909449
19.
A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma.
Breast Cancer Res Treat
; 115(3): 609-12, 2009 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-18751888
20.
A Pilot Study of Dose-Dense Paclitaxel With Trastuzumab and Lapatinib for Node-negative HER2-Overexpressed Breast Cancer.
Clin Breast Cancer
; 16(2): 87-94, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26454612